Nanobiotix SA, of Paris, reported intermediate data from a phase I/II trial testing NBTXR-3, hafnium oxide nanoparticles, in liver cancers, including primary hepatocellular cancer and liver metastasis from other tumors, at the ASCO Gastrointestinal Cancers Symposium in San Francisco. Of the seven evaluable patients, three achieved a complete response and three were partial responders.